Literature DB >> 23180437

Founder effects in two predominant intronic mutations of UNC13D, c.118-308C>T and c.754-1G>C underlie the unusual predominance of type 3 familial hemophagocytic lymphohistiocytosis (FHL3) in Korea.

Ja Young Seo1, Joon-Sup Song, Ki-O Lee, Hong-Hee Won, Jong-Won Kim, Sun-Hee Kim, Soo-Hyun Lee, Keon-Hee Yoo, Ki-Woong Sung, Hong Hoe Koo, Hyoung Jin Kang, Hee Young Shin, Hyo-Seop Ahn, Dong Kyun Han, Hoon Kook, Tai Ju Hwang, Chuhl-Joo Lyu, Mi-Jung Lee, Ji-Yoon Kim, Sung-Shik Park, Young-Tak Lim, Bo-Eun Kim, Kyung-Nam Koh, Ho Joon Im, Jong Jin Seo, Hee-Jin Kim.   

Abstract

Familial hemophagocytic lymphohistiocytosis (familial HLH or FHL) is a potentially fatal autosomal recessive disorder. Our previous study demonstrated that UNC13D mutations (FHL3) account for ~90 % of FHL in Korea with recurrent splicing mutation c.754-1G>C (IVS9-1G>C). Notably, half of the FHL3 patients had a monoallelic mutation of UNC13D. Deep intronic mutations in UNC13D were recently reported in patients of European descent. In this study, we performed targeted mutation analyses for deep intronic mutations and investigated on the founder effect in FHL3 in Korean patients. The study patients were 72 children with HLH including those with FHL3 previously reported to have a monoallelic UNC13D mutation. All patients were recruited from the Korean Registry of Hemophagocytic Lymphohistiocytosis. In addition to conventional sequencing of FHL2-4, targeted tests for c.118-308C>T and large intronic rearrangement mutations of UNC13D were performed. Haplotype analysis was performed for founder effects using polymorphic markers in the FHL3 locus. FHL mutations were detected in 20 patients (28 %). Seventeen patients had UNC13D mutations (FHL3, 85 %) and three had PRF1 mutations (FHL2, 15 %). UNC13D:c.118-308C>T was detected in ten patients, accounting for 38 % of all mutant alleles of UNC13D, followed by c.754-1G>C (26 %). Haplotype analyses revealed significantly shared haplotypes in both c.118-308C>T and c.754-1G>C, indicating the presence of founder effects. The deep intronic mutation UNC13D:c.118-308C>T accounts for the majority of previously missing mutations and is the most frequent mutation in FHL3 in Korea. Founder effects of two recurrent intronic mutations of UNC13D explain the unusual predominance of FHL3 in Korea.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23180437     DOI: 10.1007/s00277-012-1628-6

Source DB:  PubMed          Journal:  Ann Hematol        ISSN: 0939-5555            Impact factor:   3.673


  16 in total

1.  Lentiviral Gene Therapy for Familial Hemophagocytic Lymphohistiocytosis Type 3, Caused by UNC13D Genetic Defects.

Authors:  Sarah E Takushi; Na Yoon Paik; Andrew Fedanov; Chengyu Prince; Christopher B Doering; H Trent Spencer; Shanmuganathan Chandrakasan
Journal:  Hum Gene Ther       Date:  2020-06       Impact factor: 5.695

2.  Mutation Spectrum of STAR and a Founder Effect of the p.Q258* in Korean Patients with Congenital Lipoid Adrenal Hyperplasia.

Authors:  Eungu Kang; Yoon-Myung Kim; Gu-Hwan Kim; Beom Hee Lee; Han-Wook Yoo; Jin-Ho Choi
Journal:  Mol Med       Date:  2017-05-02       Impact factor: 6.354

3.  Predictive value of surveillance cultures for bacteremia caused by extended-spectrum beta-lactamase (ESBL)-producing Enterobacterales among patients with hematological diseases.

Authors:  Takuya Hattori; Tatsunori Goto; Masahide Osaki; Yukiyasu Ozawa; Koichi Miyamura
Journal:  Infection       Date:  2022-01-10       Impact factor: 3.553

4.  Frequency and spectrum of disease-causing variants in 1892 patients with suspected genetic HLH disorders.

Authors:  Vanessa Gadoury-Levesque; Lei Dong; Rui Su; Jianjun Chen; Kejian Zhang; Kimberly A Risma; Rebecca A Marsh; Miao Sun
Journal:  Blood Adv       Date:  2020-06-23

5.  Transcriptional regulation of Munc13-4 expression in cytotoxic lymphocytes is disrupted by an intronic mutation associated with a primary immunodeficiency.

Authors:  Frank Cichocki; Heinrich Schlums; Hongchuan Li; Vanessa Stache; Timothy Holmes; Todd R Lenvik; Samuel C C Chiang; Jeffrey S Miller; Marie Meeths; Stephen K Anderson; Yenan T Bryceson
Journal:  J Exp Med       Date:  2014-05-19       Impact factor: 14.307

6.  First report on familial hemophagocytic lymphohistiocytosis with an abnormal immunophenotype and T cell monoclonality in Korea.

Authors:  Sang-Yong Shin; Kyunghoon Lee; Mi-Ae Jang; Seung-Tae Lee; Keon Hee Yoo; Hong Hoe Koo; Dae Shick Kim; Hee-Jin Kim; Sun-Hee Kim
Journal:  Ann Lab Med       Date:  2014-12-08       Impact factor: 3.464

7.  Familial Hemophagocytic Lymphohistiocytosis Type 2 in a Korean Infant With Compound Heterozygous PRF1 Defects Involving a PRF1 Mutation, c.1091T>G.

Authors:  Min Sun Kim; Young Uk Cho; Seongsoo Jang; Eul Ju Seo; Ho Joon Im; Chan Jeoung Park
Journal:  Ann Lab Med       Date:  2017-03       Impact factor: 3.464

8.  Genetic and mechanistic diversity in pediatric hemophagocytic lymphohistiocytosis.

Authors:  Ivan K Chinn; Olive S Eckstein; Erin C Peckham-Gregory; Baruch R Goldberg; Lisa R Forbes; Sarah K Nicholas; Emily M Mace; Tiphanie P Vogel; Harshal A Abhyankar; Maria I Diaz; Helen E Heslop; Robert A Krance; Caridad A Martinez; Trung C Nguyen; Dalia A Bashir; Jordana R Goldman; Asbjørg Stray-Pedersen; Luis A Pedroza; M Cecilia Poli; Juan C Aldave-Becerra; Sean A McGhee; Waleed Al-Herz; Aghiad Chamdin; Zeynep H Coban-Akdemir; Shalini N Jhangiani; Donna M Muzny; Tram N Cao; Diana N Hong; Richard A Gibbs; James R Lupski; Jordan S Orange; Kenneth L McClain; Carl E Allen
Journal:  Blood       Date:  2018-04-09       Impact factor: 25.476

9.  Comparison of Th1/Th2 cytokine profiles between primary and secondary haemophagocytic lymphohistiocytosis.

Authors:  Yuanyuan Chen; Zhujun Wang; Zebin Luo; Ning Zhao; Shilong Yang; Yongmin Tang
Journal:  Ital J Pediatr       Date:  2016-05-21       Impact factor: 2.638

10.  Genetic predisposition to hemophagocytic lymphohistiocytosis: Report on 500 patients from the Italian registry.

Authors:  Valentina Cetica; Elena Sieni; Daniela Pende; Cesare Danesino; Carmen De Fusco; Franco Locatelli; Concetta Micalizzi; Maria Caterina Putti; Andrea Biondi; Franca Fagioli; Lorenzo Moretta; Gillian M Griffiths; Lucio Luzzatto; Maurizio Aricò
Journal:  J Allergy Clin Immunol       Date:  2015-09-02       Impact factor: 10.793

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.